Ampio : Ampion Shows Reduction In Pain & Improvement In Function At 12 Weeks In Severe OAK Patients

(RTTNews) - Ampio Pharmaceuticals (AMPE) announced positive results from AP-013, a randomized, saline-controlled, double-blind Phase III clinical study evaluating the efficacy of an intra-articular (IA) injection of Ampion in adults with pain due to severe osteoarthritis of the knee or OAK.

In the study, Ampion demonstrated a statistically significant reduction in pain and improvement in function at 12 weeks in severe OAK patients.

Ampio said its current cash runway of approximately 12 months expected to provide sufficient near-term liquidity and flexibility to support existing business operations.

Ampio plans to meet with the U.S. Food and Drug Administration to discuss the Phase III results and Biologics License Application.